Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: The experience of Japanese multi-institutions

BJU International

Volumn 112, Issue 2, 2013, Pages

  Tanaka, Nobuyuki ^a,d   Kikuchi, Eiji ^a   Kanao, Kent ^a   Matsumoto, Kazuhiro ^a,b   Kobayashi, Hiroaki ^a,c   Miyazaki, Yasumasa ^a,e   Ide, Hiroki ^f,g   Obata, Jun ^a,j   Hoshino, Katsura ^a,k   Shirotake, Suguru ^a,f   Hayakawa, Nozomi ^a,b   Kosaka, Takeo ^a,i   Miyajima, Akira ^a   Momma, Tetsuo ^h   Nakagawa, Ken ^a   Hasegawa, Shintaro ^j   Nakajima, Yosuke ^k   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^d Musashino Hospital   (Japan)

^e Ogikubo Hospital   (Japan)

^f Inagi City Hospital   (Japan)

^g Saitama City Hospital   (Japan)

^h SAITAMA NATIONAL HOSPITAL   (Japan)

ⁱ Irumagawa Hospital   (Japan)

^j National Hospital Organization Tochigi Medical Center   (Japan)

^k SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

more..

Author keywords

metastasis; nephroureterectomy; outcome; upper urinary tract; urothelial carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN CHARACTERISTIC; INSTITUTIONAL CARE; INTERMEDIATE RISK POPULATION; JAPANESE; LIVER METASTASIS; LOW RISK POPULATION; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RADICAL NEPHROURETERECTOMY; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; NEPHRECTOMY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URETER; URETERAL NEOPLASMS;

EID: 84879626350     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12133     Document Type: Article

References (26)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236
2. Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011; 59: 584-594
3. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG,. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998; 52: 594-601
4. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224-1233
5. Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2012; 61: 818-825
6. Yates DR, Hupertan V, Colin P, et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer 2012; 106: 1083-1088
7. Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012; 62: 100-114
8. Kikuchi E, Margulis V, Karakiewicz PI, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 2009; 27: 612-618
9. Margulis V, Youssef RF, Karakiewicz PI, et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 2010; 184: 453-458
10. Zigeuner R, Shariat SF, Margulis V, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 2010; 57: 575-581
11. Martinez-Salamanca JI, Shariat SF, Rodriguez JC, et al. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2012; 109: 1155-1161
12. Ariane MM, Colin P, Ouzzane A, et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012; 19: 301-308
13. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
14. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-3181
15. Sengelov L, Kamby C, von der Maase H,. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 2001; 39: 634-642
16. Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95: 751-757
17. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608
18. Bamias A, Efstathiou E, Moulopoulos LA, et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 2005; 16: 307-313
19. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-1855
20. Shariat SF, Godoy G, Lotan Y, et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int 2010; 105: 1672-1677
21. Chromecki TF, Ehdaie B, Novara G, et al. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World J Urol 2011; 29: 473-480
22. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet 2009; 374: 239-249
23. Bellmunt J, Guix M,. New agents for bladder cancer. Ann Oncol 2010; 21 (Suppl. 7): vii56-58
24. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ,. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010; 11: 861-870
25. Shah JB, McConkey DJ, Dinney CP,. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 2011; 17: 2608-2612
26. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011; 29: 1525-1530 Technology